Research and Innovation
The idea of a vaccine for cancer is not new. But there are differences between human viruses and cancer that make creation of a cancer vaccine particularly challenging.
Resident memory T cells that enter a patient’s skin and blood during immunotherapy are behind the excellent and long-lasting immune responses to cancer that some survivors develop.
Combining high-dose radiation therapy with immunotherapy to treat cancer, and resolving employment challenges among cancer survivors are among the newest research projects funded by The Prouty.
Researchers convert a standard linear accelerator used for radiation therapy, to deliver an ultra-high-dose rate beam to cancer patients “in a flash.”
In this Q&A series, Jason Faris, MD details some exciting and innovating early-phase trials underway at the cancer center.